<div id="readability-page-1" class="page"><div><div> Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER – Baystreet.ca News Commentary – The medical imaging market is pivoting toward strict economic accountability. AI cardiac platforms are projected to hit a $2.57 trillion valuation in 2026 as providers demand real financial returns from their digital investments[1]. This structural shift sees management systems handling massive data volumes across enterprise networks to deliver precision at scale[2]. This convergence of MRI accuracy and subscription economics positions VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), LifeMD (NASDAQ: LFMD), Hims &amp; Hers (NYSE: HIMS), Teladoc Health (NYSE: TDOC), and Omada Health (NASDAQ: OMDA) as leaders in this clinical and financial fusion. The healthcare SaaS market expanded to $42.54 billion in 2026[3]. This growth reflects a movement toward recurring revenue models that tie tech spending to actual performance outcomes. Most systems now require a solid ROI proof within six to nine months[4]. This makes Device-as-a-Service the new standard for facilities looking to slash staffing costs while improving heart health results. Ventripoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) is building a subscription business around technology that converts standard 2D ultrasound images into detailed 3D heart models with MRI-level accuracy. The system delivers precise cardiac assessments at a fraction of the cost and complexity of traditional MRI imaging. Strong investor demand recently doubled the company's private placement from $500,000 to $1 million. The capital will fund commercialization activities, manufacturing scale-up, regulatory submissions across additional markets, and operational requirements as the company transitions from development to revenue generation. The latest strategic move focuses on proving economic value rather than just clinical capability. Ventripoint engaged Summit Sciences, a specialized healthcare consulting firm, to develop ROI models that show hospitals exactly what they will save. These models integrate real-world data to demonstrate measurable returns through process improvements, enhanced diagnostic accuracy, and optimized resource allocation. &#34;We are excited to partner with Dana and Summit Sciences to elevate our financial modeling capabilities,&#34; said Hugh MacNaught, President and CEO of Ventripoint Diagnostics. &#34;Dana's extensive expertise in healthcare transformation, combined with Summit Sciences' proven track record in data-driven consulting, will enable us to deliver even more compelling value propositions to our customers. This initiative underscores our commitment to not only advancing cardiac care through technology but also ensuring that our solutions make strong economic sense for healthcare providers worldwide.&#34; Dana Friesen leads Summit Sciences as CEO, bringing more than 15 years of experience in financial analysis and ROI optimization within the medical device sector. The firm has delivered billions in cumulative savings for clinical partners. Friesen's work with indigenous health networks aligns with Ventripoint's expansion into underserved markets. The company announced a partnership with Nisga'a Valley Health Authority establishing a model for delivering advanced cardiac imaging to remote and Indigenous communities. The collaboration uses a hub-and-spoke design where local providers acquire ultrasound scans and transmit them digitally to specialists at a central hub for rapid interpretation. Ventripoint appointed David Swetlow as Chief Financial Officer. Swetlow brings more than 15 years of senior management experience from high-growth medical technology companies including Sernova, Ondine, Protox, HealthPricer, and QLT. Management views the appointment as a key step in executing a commercial strategy designed to accelerate market adoption and drive revenue growth. The company also issued a corporate update detailing its Device-as-a-Service subscription model. Management believes this approach shortens sales cycles and builds recurring revenue streams while making the technology accessible to more healthcare facilities without requiring large upfront capital investments. CONTINUED… Read this and more news for VentriPoint Diagnostics at: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint In other industry developments and happenings in the market include: LifeMD (NASDAQ: LFMD) has expanded its collaboration with Novo Nordisk as a recognized telehealth partner offering the approved Wegovy pill, the first FDA-approved oral GLP-1 therapy for chronic weight management. Eligible patients can access Wegovy pill for as little as $149 per month through LifeMD's end-to-end telehealth platform, with the approval supported by Phase 3 trial data showing 16.6% mean weight loss versus 2.7% with placebo. &#34;In close collaboration with Novo Nordisk, we moved quickly to bring the Wegovy pill to patients through LifeMD at the attractive cash-pay price, reinforcing our role as a preferred virtual care partner for evidence-based medical weight management,&#34; said Justin Schreiber, Chairman and CEO of LifeMD. &#34;We believe oral GLP-1 therapies represent an important next phase in diabetes and weight care.&#34; LifeMD is featured on the NovoCare and Wegovy websites as a trusted provider, reflecting growing demand for convenient access to branded pharmaceutical therapies. The company's integration with NovoCare Pharmacy provides patients with comprehensive clinical support including consultations, ongoing oversight, diagnostic testing, and coordinated pharmacy fulfillment with fast shipping. Hims &amp; Hers (NYSE: HIMS) launched its comprehensive Weight Loss Programme in the United Kingdom, officially introducing the Hers platform to provide eligible women access to holistic weight management care. The expansion addresses a critical need as 64% of UK adults are overweight or living with obesity, yet access to GLP-1 treatment plans remains challenging through both NHS and private sectors. &#34;The launch of Hims &amp; Hers' comprehensive Weight Loss Programme and the vital introduction of the Hers platform, our dedicated platform for women, represents a significant deepening of our commitment to the UK,&#34; said David Meinertz, GM International of Hims &amp; Hers. &#34;Our doctor-designed treatment plans will complement the NHS by providing accessible, evidence-based, and sustainable long-term weight management care to those who need it, discreetly and conveniently.&#34; Following thorough clinical assessments by GMC-registered doctors, eligible customers access transparent pricing and personalized programmes including branded GLP-1 options such as Mounjaro or Wegovy alongside oral treatment Orlos. Hims &amp; Hers provides comprehensive support including 24/7 care team access and content addressing nutrition, movement, and sleep habits to support sustainable long-term health outcomes for millions battling obesity. Teladoc Health (NYSE: TDOC) has launched new enhancements to its 24/7 Care service, enabling care teams to address a broader spectrum of health needs through its Prism care delivery platform. The enhanced service now treats a wider range of conditions including back and joint pain, hair loss, and sleep issues, while providing specialist consults, preventive care referrals, and real-time prescription benefit checks during virtual urgent care visits. &#34;As the pioneer in virtual care, we continue to innovate and raise expectations about the value that can be created in virtual visits,&#34; said Kelly Bliss, President of U.S. Group Health at Teladoc Health. &#34;Our clinical expertise, purpose-built technology, and operational scale are unmatched and enable us to deliver meaningful outcomes and measurable ROI for our customers.&#34; More than 100 million Americans have access to at least one Teladoc Health service through their health plan or employer. Recent data show more than 95% of member concerns are addressed in a single 24/7 Care visit, while early data demonstrates 70% of members agreed to take action on preventive care recommendations made during visits. Omada Health (NASDAQ: OMDA) has announced results from a 12-month real-world analysis demonstrating that members in its GLP-1 companion program who persisted on medication achieved 18.4% average weight loss, compared to 11.9% seen in real world evidence. The analysis followed 965 members without diabetes participating in Omada Health's Enhanced GLP-1 Care Track, with findings showing 67% of members remained on their GLP-1 medications through one year versus a 47-49% persistence rate in comparable studies. &#34;The promise of GLP-1s is clear: significant weight loss that unlocks broader health benefits. But that promise requires persistence through real-world challenges,&#34; said Wei-Li Shao, President at Omada Health. &#34;These outcomes demonstrate that with the right support, members can achieve the weight loss they need to improve their health. That's how behavioral support transforms medication coverage from a cost into an investment.&#34; The company recently launched new capabilities for prescribing and medication management of anti-obesity medications including GLP-1s to tailor support before, during, and after medication treatment. Omada Health has served over one million members since launch across more than 2,000 customers, with 30 peer-reviewed publications showcasing its clinical and economic results. Article Source: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint CONTACT: Baystreet.ca [email protected] (805) 649-0042 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. SOURCES: 1. https://www.globenewswire.com/news-release/2026/01/23/3224892/0/en/AI-in-Medical-Imaging-Market-Size-to-Hit-Nearly-USD-22-97-Trillion-by-2035-Driven-by-Rising-Demand-for-Early-Disease-Detection-and-Workflow-Automation.html 2. https://www.prnewswire.com/news-releases/medical-image-management-market-surges-to-usd-10-2-billion-by-2033--propelled-by-9-8-cagr---verified-market-reports-302668011.html 3. https://www.precedenceresearch.com/healthcare-software-as-a-service-market 4. https://openloophealth.com/blog/recent-digital-health-trends-insight-and-news-december-2025</div></div></div>

The medical imaging market is shifting towards economic accountability, with AI cardiac platforms expected to reach a $2.57 trillion valuation by 2026. Companies like VentriPoint Diagnostics are leading this change by developing subscription models that enhance cardiac imaging accuracy while reducing costs. VentriPoint's recent funding increase to $1 million will support commercialization and regulatory efforts. The company is also partnering with Summit Sciences to create ROI models for hospitals, emphasizing economic value alongside clinical capabilities. Additionally, LifeMD and Hims & Hers are expanding their telehealth services in the weight management sector.

Baystreet

Hims & Hers Health

iShares US Healthcare Providers

ALPS Medical Breakthrough

SPDR S&P Health

iShares Biotechnology ETF

LifeMD

Bluejay Diagnostics

Invesco Biotechnology & Genome ETF

Defiance Daily Target 2X Long HIMS ETF

Health Care Select Sector SPDR

Bioventus

First Trust NYSE Arca Biotech Index Fd

Defiance Leveraged Long +Income HIMS ETF

VanEck Biotech ETF

iShares US Medical Devices

Co-Diagnostic

The 2026 Healthcare Reset: Subscription Economics Meets MRI-Grade AI Precision